157 related articles for article (PubMed ID: 38599221)
41. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Frias JP; Hsia S; Eyde S; Liu R; Ma X; Konig M; Kazda C; Mather KJ; Haupt A; Pratt E; Robins D
Lancet; 2023 Aug; 402(10400):472-483. PubMed ID: 37369232
[TBL] [Abstract][Full Text] [Related]
42. Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi TJ; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Böhm M; Brueckmann M; Chopra VK; Iwata T; Januzzi J; Piña IL; Ponikowski P; Senni M; Vedin O; Verma S; Zhang Y; Zannad F; Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1623-1631. PubMed ID: 36974746
[TBL] [Abstract][Full Text] [Related]
43. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
44. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
45. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT; Frias JP; Jastreboff AM; le Roux CW; Sattar N; Aizenberg D; Mao H; Zhang S; Ahmad NN; Bunck MC; Benabbad I; Zhang XM;
Lancet; 2023 Aug; 402(10402):613-626. PubMed ID: 37385275
[TBL] [Abstract][Full Text] [Related]
46. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
47. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
[TBL] [Abstract][Full Text] [Related]
48. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Aroda VR; Aberle J; Bardtrum L; Christiansen E; Knop FK; Gabery S; Pedersen SD; Buse JB
Lancet; 2023 Aug; 402(10403):693-704. PubMed ID: 37385279
[TBL] [Abstract][Full Text] [Related]
50. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
51. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
52. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
[TBL] [Abstract][Full Text] [Related]
53. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
[TBL] [Abstract][Full Text] [Related]
54. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
55. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
[TBL] [Abstract][Full Text] [Related]
56. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
57. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
[TBL] [Abstract][Full Text] [Related]
58. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
59. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
[TBL] [Abstract][Full Text] [Related]
60. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
